Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
Doroshow DB, LoRusso PM. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. Future Oncology 2017, 14: 589-602. PMID: 29214842, DOI: 10.2217/fon-2017-0477.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedBreast NeoplasmsCell ProliferationClinical Trials as TopicDisease-Free SurvivalFemaleHumansImmunoconjugatesMaytansineReceptor, ErbB-2TrastuzumabConceptsBreast cancerAnti-HER2 monoclonal antibody trastuzumabManagement of HER2Single-agent trastuzumabTumor-directed cytotoxicityAcceptable toxicity profileFirst-line treatmentPhase III trialsMonoclonal antibody trastuzumabAdjuvant managementIII trialsOverall survivalAdvanced HER2Cardiac toxicityTrastuzumab emtansineAgent trastuzumabToxicity profileAntibody trastuzumabSystemic toxicityHER2CancerTrastuzumabStable linkerOngoing studiesToxicity